MICHELLE THOMAS: Open Payments
NPI 1396273645 · HYANNIS, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,277 in 55 payments from 17 companies in 2025. Trend: 2023 $82 · 2024 $338 · 2025 $1,277
Food & beverage: $1,277
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $334 |
| GlaxoSmithKline, LLC. | 5 | $205 |
| Alnylam Pharmaceuticals Inc. | 5 | $110 |
| ABBVIE INC. | 4 | $98 |
| Novartis Pharmaceuticals Corporation | 4 | $85 |
| Eisai Inc. | 3 | $79 |
| Lilly USA, LLC | 3 | $67 |
| Phathom Pharmaceuticals, Inc. | 3 | $61 |
| Novo Nordisk Inc | 3 | $49 |
| Verona Pharma, Inc. | 2 | $44 |
Products named: FARXIGA, AREXVY, AIRSUPRA, ONPATTRO, LEQVIO, BREZTRI, Leqembi, QULIPTA.
Industry payments across MA — which companies pay providers there.
